Emerald Advisers LLC Sells 51,470 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Emerald Advisers LLC cut its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 9.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 518,328 shares of the biopharmaceutical company’s stock after selling 51,470 shares during the period. Emerald Advisers LLC owned approximately 0.56% of Ultragenyx Pharmaceutical worth $21,806,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Ultragenyx Pharmaceutical by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 10,034,862 shares of the biopharmaceutical company’s stock valued at $422,167,000 after buying an additional 89,389 shares during the last quarter. Alkeon Capital Management LLC boosted its stake in Ultragenyx Pharmaceutical by 34.3% during the third quarter. Alkeon Capital Management LLC now owns 3,011,716 shares of the biopharmaceutical company’s stock valued at $167,301,000 after buying an additional 769,884 shares during the last quarter. Baker BROS. Advisors LP boosted its holdings in shares of Ultragenyx Pharmaceutical by 7.5% in the 3rd quarter. Baker BROS. Advisors LP now owns 1,576,114 shares of the biopharmaceutical company’s stock worth $87,553,000 after purchasing an additional 109,567 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 4.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,571,081 shares of the biopharmaceutical company’s stock worth $87,296,000 after purchasing an additional 65,623 shares during the period. Finally, Two Sigma Advisers LP boosted its holdings in shares of Ultragenyx Pharmaceutical by 123.4% in the 3rd quarter. Two Sigma Advisers LP now owns 987,800 shares of the biopharmaceutical company’s stock worth $54,872,000 after purchasing an additional 545,600 shares during the period. 97.67% of the stock is owned by institutional investors.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Thomas Richard Kassberg sold 6,028 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $253,778.80. Following the sale, the executive vice president now owns 265,238 shares in the company, valued at approximately $11,166,519.80. The trade was a 2.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Theodore Alan Huizenga sold 967 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $40,710.70. Following the sale, the chief accounting officer now owns 50,265 shares in the company, valued at approximately $2,116,156.50. The trade was a 1.89 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 136,370 shares of company stock worth $5,751,499. 5.80% of the stock is currently owned by insiders.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE stock opened at $39.18 on Friday. Ultragenyx Pharmaceutical Inc. has a 1-year low of $37.02 and a 1-year high of $60.37. The stock’s fifty day moving average price is $41.88 and its 200 day moving average price is $47.45. The company has a market cap of $3.62 billion, a price-to-earnings ratio of -6.18 and a beta of 0.67.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The business had revenue of $164.88 million for the quarter, compared to analysts’ expectations of $163.23 million. As a group, equities research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Wall Street Analysts Forecast Growth

RARE has been the subject of a number of research analyst reports. Wedbush reissued a “neutral” rating and set a $48.00 price target (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. Wells Fargo & Company lifted their target price on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a research report on Friday, December 20th. Piper Sandler decreased their target price on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating for the company in a research report on Monday, March 17th. Canaccord Genuity Group lifted their target price on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a “buy” rating in a research report on Tuesday, February 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $91.71.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.